US 2015/0307492 A1 · 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease

Abstract

The present invention relates to a compound of formula (I′) or a pharmaceutically acceptable salt, solvate or hydrate thereof, in which: X3 is F, OH or SH, Y3 is F, OH or SH, X1, X2, X4, X5, Y1, Y2, Y4 and Y5 are, independently of one another, H, F, Cl, Br, OH or SH, and 1 to 2 groups among the X1, X2, X4 and X5 radicals are other than H and/or 1 to 2 groups among the Y1, Y2, Y4 and Y5 radicals are other than H. The present invention also relates to a compound of formula (I′) for use as a medicament, in particular in the prevention and/or treatment of cognitive disorders associated with a dysfunction of the Dyrk1A protein.

Claims25

Dependent claims

A compound of formula (I′) or one of the pharmaceutically acceptable salts, solvates and hydrates thereof:

wherein:
X3 is F, OH or SH,
Y3 is F, OH or SH,
X1, X2, X4, X5, Y1, Y2, Y4 and Y5 independently of one another are H, F, Cl, Br, OH or SH, and
one to two groups among radicals X1, X2, X4 and X5 are different from H and/or one to two groups among radicals Y1, Y2, Y4 and Y5 are different from H.

2 more elements

Dependencies are inferred from the claim text.

3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease

Life of this patent

3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease

Life of this patent

Abstract

Claims25